Israël - Hebreeuws - Ministry of Health

unipharm ltd, israel - azithromycin as dihydrate - טבליות מצופות - azithromycin as dihydrate 250 mg - azithromycin

Israël - Hebreeuws - Ministry of Health

kamada ltd, israel - alpha-1-antitrypsin ( aat) - תמיסה לאינפוזיה - alpha-1-antitrypsin ( aat) 1 g / 50 ml - alfa1 antitrypsin

Israël - Hebreeuws - Ministry of Health

bioavenir ltd, israel - azithromycin as dihydrate - אבקה להכנת תמיסה מרוכזת לעירוי - azithromycin as dihydrate 500 mg/vial - azithromycin

Israël - Hebreeuws - Ministry of Health

mbi pharma ltd., israel - azithromycin as dihydrate - אבקה להכנת תמיסה לאינפוזיה - azithromycin as dihydrate 500 mg - azithromycin

Israël - Hebreeuws - Ministry of Health

teva pharmaceutical industries ltd, israel - azithromycin - אבקה להכנת תרחיף - azithromycin 200 mg / 5 ml - azithromycin

Israël - Hebreeuws - Ministry of Health

a.l. medi-market ltd. - azithromycin as dihydrate - אבקה להכנת תמיסה לאינפוזיה - azithromycin as dihydrate 500 mg/vial - azithromycin

Israël - Hebreeuws - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

Israël - Hebreeuws - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

Israël - Hebreeuws - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

Israël - Hebreeuws - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.